Tonix Pharmaceuticals to Present at Key Investor Conferences in August and September

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has announced that its management team will participate in two prominent investor conferences scheduled for August and September 2026. The company's President and CEO, Dr. Seth Lederman, will engage in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, from 1:30 p.m. to 1:55 p.m. ET. Additionally, Dr. Lederman will hold one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 16.

These appearances are strategic opportunities for Tonix to discuss its business operations, pipeline developments, and future prospects with the investment community. The company's participation underscores its proactive approach to investor relations and its commitment to transparency as it navigates the commercial landscape.

Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on developing treatments for central nervous system (CNS) and immunology conditions with high unmet medical needs. The company's flagship product, TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), recently received approval and represents the first new treatment for fibromyalgia in over 15 years. This approval marks a significant milestone for the company, positioning it to address a patient population that has long awaited new therapeutic options.

The company's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace® SymTouch® and Tosymra®. Tonix is also exploring the broader potential of TONMYA through Phase 2 clinical trials evaluating its efficacy in major depressive disorder and acute stress disorder. Furthermore, the CNS pipeline includes TNX-2900, a Phase 2-ready candidate for the treatment of Prader-Willi syndrome, a rare genetic disorder.

In addition to its CNS focus, Tonix is advancing a pipeline of immunology programs. These include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. The diversity of the pipeline reflects the company's commitment to addressing a range of serious health conditions.

It is important to note that Tonix's product development candidates are investigational drugs or biologics, and their efficacy and safety have not yet been established, nor have they been approved for any indication. This cautionary statement is a reminder of the inherent uncertainties in pharmaceutical development.

The investor conferences provide a platform for Tonix to highlight its progress and future direction. For more detailed information about the company's participation, the full press release is available at https://ibn.fm/DKFAC. Additionally, the latest news and updates regarding TNXP can be found in the company's newsroom at https://ibn.fm/TNXP.